Royalty Pharma plc (NASDAQ:RPRX) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Royalty Pharma Plc (RPRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 16,968,321 | $432,861,869 | +43% | 0.75% |
| 2. | Viking Global Andreas Halvorsen | 12,207,885 | $311,423,146 | +1% | 1% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 3,673,200 | $93,703,332 | +22% | 0.21% |
| 4. | GMT Capital Thomas E. Claugus | 3,267,700 | $83,359,027 | +6% | 4.06% |
| 5. | Citadel Investment Group Ken Griffin | 2,897,964 | $73,927,062 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | Large Shareholder, Officer, Director | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | Large Shareholder, Officer, Director | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | Large Shareholder, Officer, Director | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | Large Shareholder, Officer, Director | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | Large Shareholder, Officer, Director | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.55 | 35,702 | Director | 20,099 | 2024-01-04 | Filing | |
| $27.79 | 199,098 | Director | 55,801 | 2024-01-03 | Filing | |
| $28.52 | 235,200 | Director | 254,899 | 2024-01-02 | Filing | |
| $28.04 | 65,803 | 2,477,520 | 2023-12-29 | Filing | ||
| $28.20 | 209,863 | 2,543,323 | 2023-12-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,677,448 | $1,141,768,956 | 0.02% | |
| 2. | 24,555,862 | $764,423,996 | 0.02% | |
| 3. | 13,402,284 | $417,213,100 | 0.36% | |
| 4. | 3,623,134 | $112,788,161 | 0.12% | |
| 5. | 3,122,531 | $97,204,390 | 0.02% |
News See All
Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
15 Best Defensive Stocks Amid Market Volatility
With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their money while still earning steady returns.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
Billionaire Hedge Funds
